These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
142 related items for PubMed ID: 16398152
1. [Analysis of paraoxonase activity and lipid profile in lupus patients]. Kiss E, Seres I, Zsolt K, Tarr T, Csípo I, Szegedi G, Paragh G. Orv Hetil; 2005 Nov 20; 146(47):2395-402. PubMed ID: 16398152 [Abstract] [Full Text] [Related]
2. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Kiss E, Seres I, Tarr T, Kocsis Z, Szegedi G, Paragh G. Ann N Y Acad Sci; 2007 Jun 20; 1108():83-91. PubMed ID: 17893973 [Abstract] [Full Text] [Related]
3. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. Dirican M, Akca R, Sarandol E, Dilek K. J Nephrol; 2004 Jun 20; 17(6):813-8. PubMed ID: 15593056 [Abstract] [Full Text] [Related]
4. Serum paraoxonase/arylesterase activities in phenylketonuric patients on diet. Schulpis KH, Bartzeliotou A, Tsakiris S, Gounaris A, Papassotiriou I. Eur J Clin Nutr; 2007 Jun 20; 61(6):803-8. PubMed ID: 17203019 [Abstract] [Full Text] [Related]
5. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks. Sumegová K, Blazícek P, Waczulíková I, Zitnanová I, Duracková Z. Acta Biochim Pol; 2006 Jun 20; 53(4):783-7. PubMed ID: 17106515 [Abstract] [Full Text] [Related]
6. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus. Dullaart RP, de Vries R, Sluiter WJ, Voorbij HA. Clin Endocrinol (Oxf); 2009 Feb 20; 70(2):221-6. PubMed ID: 18505467 [Abstract] [Full Text] [Related]
7. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Sarandol A, Sarandol E, Eker SS, Karaagac EU, Hizli BZ, Dirican M, Kirli S. Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug 30; 30(6):1103-8. PubMed ID: 16716479 [Abstract] [Full Text] [Related]
8. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus. Juretić D, Motejlkova A, Kunović B, Rekić B, Flegar-Mestrić Z, Vujić L, Mesić R, Lukac-Bajalo J, Simeon-Rudolf V. Acta Pharm; 2006 Mar 30; 56(1):59-68. PubMed ID: 16613735 [Abstract] [Full Text] [Related]
9. Changes of serum paraoxonase (an HDL-cholesterol-associated lipophilic antioxidant) and arylesterase activities in severe preeclamptic women. Kumru S, Aydin S, Gursu MF, Ozcan Z. Eur J Obstet Gynecol Reprod Biol; 2004 Jun 15; 114(2):177-81. PubMed ID: 15140512 [Abstract] [Full Text] [Related]
10. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Paragh G, Balla P, Katona E, Seres I, Egerházi A, Degrell I. Eur Arch Psychiatry Clin Neurosci; 2002 Apr 15; 252(2):63-7. PubMed ID: 12111338 [Abstract] [Full Text] [Related]
11. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus. Chung CP, Oeser A, Solus J, Avalos I, Gebretsadik T, Shintani A, Linton MF, Fazio S, Stein CM. J Rheumatol; 2007 Sep 15; 34(9):1849-54. PubMed ID: 17659756 [Abstract] [Full Text] [Related]
12. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Juretić D, Tadijanović M, Rekić B, Simeon-Rudolf V, Reiner E, Baricić M. Croat Med J; 2001 Apr 15; 42(2):146-50. PubMed ID: 11259735 [Abstract] [Full Text] [Related]
13. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Karp I, Abrahamowicz M, Fortin PR, Pilote L, Neville C, Pineau CA, Esdaile JM. Arthritis Rheum; 2008 Feb 15; 59(2):169-75. PubMed ID: 18240259 [Abstract] [Full Text] [Related]
14. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Erem C. Clin Endocrinol (Oxf); 2006 Mar 15; 64(3):323-9. PubMed ID: 16487444 [Abstract] [Full Text] [Related]
15. Paraoxonase and arylesterase activities in coronary artery disease. Gur M, Aslan M, Yildiz A, Demirbag R, Yilmaz R, Selek S, Erel O, Ozdogru I. Eur J Clin Invest; 2006 Nov 15; 36(11):779-87. PubMed ID: 17032345 [Abstract] [Full Text] [Related]
16. Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients. Yildiz A, Gur M, Demirbag R, Yilmaz R, Akyol S, Aslan M, Erel O. Clin Biochem; 2008 Jul 15; 41(10-11):779-84. PubMed ID: 18355454 [Abstract] [Full Text] [Related]
18. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. Kiss E, Soltesz P, Der H, Kocsis Z, Tarr T, Bhattoa H, Shoenfeld Y, Szegedi G. J Autoimmun; 2006 Dec 15; 27(4):211-7. PubMed ID: 17088047 [Abstract] [Full Text] [Related]
19. [Lipid profile in patients with systemic lupus erythematosus, with special focus on lipoprotein(a) in lupus nephritis]. Kiss E, Fazekas B, Tarr T, Muszbek L, Zeher M, Szegedi G. Orv Hetil; 2004 Feb 01; 145(5):217-22. PubMed ID: 15024932 [Abstract] [Full Text] [Related]
20. Synergistic effects of BuChE non-UU phenotype and paraoxonase (PON1) 55 M allele on the risk of systemic lupus erythematosus: influence on lipid and lipoprotein metabolism and oxidative stress, preliminary report. Bahrehmand F, Vaisi-Raygani A, Rahimi Z, Ahmadi R, Kiani A, Tavilani H, Vaisi-Raygani H, Pourmotabbed T. Lupus; 2014 Mar 01; 23(3):263-72. PubMed ID: 24399815 [Abstract] [Full Text] [Related] Page: [Next] [New Search]